Drug Approval | March 31, 2026
ENHERTU approved in China as first HER2-targeted ADC for early breast cancer
The decision is based on the phase 3 DESTINY-Breast11 trial
The decision is based on the phase 3 DESTINY-Breast11 trial
Sugammadex injection is bioequivalent to Merck’s Bridion injection for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
The approval covers pediatric patients without a matched sibling donor for stem cell transplant
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
Paroxetine extended-release tablets are indicated for the treatment of major depressive disorder
Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones
The move comes as drug developers face mounting pressure from faster timelines and increasingly complex manufacturing processes
As Tracky launches integrated health solution
The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026
Subscribe To Our Newsletter & Stay Updated
